Disease Landscape and Forecast Insights

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…

Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), is among the most serious manifestations of the disease. Until 2020, no therapy was…

The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…

The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…

Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) prophylaxis in cancer comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (…

The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…